Mid-Morning Market Update: U.S. Stocks Mixed; Dollar Tree Reports Mixed Q4 Results
U.S. stocks opened mixed this morning, with the Dow Jones adding more than 200 points on Wednesday.
SVB Leerink Maintains Market Perform on Karyopharm Therapeutics, Lowers Price Target to $6
SVB Leerink analyst Jonathan Chang maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Market Perform and lowers the price target from $8 to $6.
Karyopharm Plans To Initiate New Placebo-Controlled Randomized Study Of Selinexor Following FDA Discussion
Following Discussion with the FDA, Karyopharm Plans to Initiate a New Placebo-Controlled Randomized Study of Selinexor in the Advanced or Recurrent Endometrial Cancer p53 Wild-Type Population to Support a Future sNDA
Why Are Karyopharm Shares Plunging Today?
Karyopharm Therapeutics Inc (NASDAQ: KPTI) revealed that executive vice president and chief medical officer Jatin Shah departs for "other professional opportunities."
50 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Indonesia Energy Corporation Limited (NYSE: INDO) jumped 75.2% to $7.87.
Imperial Petroleum Inc. (NASDAQ: IMPP) rose 52.9% to $0.7500 after declining around 7% on Friday.
42 Stocks Moving In Friday’s Mid-Day Session
Gainers
Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 72.6% to $6.56 after jumping 17% on Thursday.
Where Karyopharm Therapeutics Stands With Analysts
Karyopharm Therapeutics (NASDAQ:KPTI) has observed the following analyst ratings within the last quarter:
